|
WO2020174023A1
|
|
Fragile x mental retardation protein interfering oligonucleotides and methods of using same
|
|
WO2020161362A1
|
|
Process of making 3-(4'-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof
|
|
WO2020152350A1
|
|
Compositions for use in preventing acne
|
|
CA3048334A1
|
|
Compositions of smad7 antisense oligonucleotide and methods of treating or preventing psoriasis
|
|
EP3481375A1
|
|
Inositol compositions and methods for using same
|
|
US2019046490A1
|
|
Methods of treating lactose intolerance
|
|
EP3420085A1
|
|
Methods of treating celiac disease using smad7 inhibition
|
|
WO2017093444A1
|
|
Compositions for oral administration in the treatment of inflammatory bowel disease
|
|
US2018338992A1
|
|
Il-34 antisense oligonucleotides and methods of using same
|
|
US2020237801A1
|
|
Methods of using smad7 antisense oligonucleotides based on biomarker expression
|
|
EP3355896A2
|
|
Methods of using smad7 antisense oligonucleotides based on biomarker expression
|
|
WO2017046343A1
|
|
Compositions for rectal administration in the treatment of ulcerative colitis and methods of using same
|
|
AU2015275229A1
|
|
Compositions for colon lavage and methods of making and using same
|
|
KR20170069262A
|
|
Methods and compositions for treating a subject with a smad7 antisense oligonucleotide
|
|
EP3213070A2
|
|
Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
|
|
KR20170031245A
|
|
Methods and compositions for diagnosing and treating inflammatory bowel disorders
|
|
EP3160964A1
|
|
Aryl receptor modulators and methods of making and using the same
|
|
US2018180630A1
|
|
Methods for treating inflammatory bowel disease
|
|
IL234767D0
|
|
Methods of treating lactose intolerance
|
|
CN105008394A
|
|
Methods of treating colorectal cancer
|
